| |
|
Drug Manufacturers - Major News
|
Sanofi-Aventis arrhythmia drug Multaq approved
Thu Jul 2 (AP)
Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago.
|
|
Top-Ranked Analysts
|
Provided by StarMine
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 880B | | Price
/ Earnings: | 13.6 | | Price
/ Book: | 7.8 | | Net
Profit Margin (mrq): | 16.4% | | Price
To Free Cash Flow (mrq): | -2920.1 | | Return
on Equity: | 19.9% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 4.4% |
|